ClinicalTrials.Veeva

Menu

AI-Driven Precision Diagnostic System for Lung Cancer Based on Liquid Biopsy

K

Korea University

Status

Completed

Conditions

Lung Cancer

Study type

Observational

Funder types

Other

Identifiers

NCT07009769
2024GR0131

Details and patient eligibility

About

The investigators aim to develop an AI-powered precision medicine system based on liquid biopsy that can comprehensively provide lung cancer patients with information on disease stage, histologic subtype, and presence of genetic mutations.

Enrollment

865 patients

Sex

All

Ages

40+ years old

Volunteers

Accepts Healthy Volunteers

Inclusion and exclusion criteria

Inclusion Criteria (Patients)

  • Republic of Korea nationality
  • Age ≥ 30 years
  • Lung cancer based on radiologic and/or histopathologic examination
  • No prior diagnosis of any other cancer and no history of anticancer treatment before the date of blood sample collection

Exclusion Criteria (Patients)

  • History of other cancers before blood collection
  • Prior cancer treatment before blood collection
  • Incomplete clinical data
  • No consent for sample use

Inclusion Criteria (Healthy Controls):

  • Republic of Korea nationality
  • No history of any cancer
  • Age ≥ 30 years

Exclusion Criteria (Healthy Controls):

  • History of any malignancy
  • Incomplete clinical information or no consent for sample use

Trial contacts and locations

1

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2025 Veeva Systems